IP Library Granted Patent US 9,359,337
Granted Patent B2
US 9,359,337 · App. 14/712,655 · Granted Jun 7, 2016

Acetamide derivatives

Inventors: Christine E. Brotherton-Pleiss (Sunnyvale, CA); Zhi Chen (Livingston, NJ); Shawn David Erickson (Leonia, NJ); Yimin Qian (Plainsboro, NJ)
Assignee: Hoffmann-La Roche Inc.
C07D413/04C07D207/09C07D211/26C07D265/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,359,337
App. No.
14/712,655
Granted
Jun 7, 2016
Kind
B2
Abstract

The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Claims (40)

1. A compound of formula (I)

wherein:

X is —CH 2 — or oxygen;

Y is —(CH 2 ) n —;

R1 is phenyl optionally substituted with halogen;

R2 is lower alkyl;

R3 is trifluoromethyl-phenyl, trifluoromethyl-pyridinyl, trifluoromethyl-pyridazinyl, trifluoromethyl-pyrimidinyl or trifluoromethyl-pyrazinyl; and

n is 0 or 1, provided that n is not 0 when X is oxygen;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein X is —CH 2 —.

3. A compound according to claim 1 , wherein X is oxygen.

4. A compound according to claim 1 , wherein n is 0.

5. A compound according to claim 1 , wherein n is 1.

6. A compound according to claim 1 , wherein R1 is halophenyl.

7. A compound according to claim 1 , wherein R1 is fluoro-phenyl.

8. A compound according to claim 1 , wherein R2 is methyl, ethyl, isopropyl or tert-butyl.

9. A compound according to claim 1 , wherein R2 is methyl, ethyl or isopropyl.

10. A compound according to claim 1 , wherein R3 is trifluoromethyl-phenyl or trifluoromethyl-pyridinyl.

11. A compound according to claim 1 , wherein, wherein R3 is trifluoromethyl-phenyl.

12. A compound according to claim 1 , wherein R3 is trifluoromethyl-pyridinyl.

13. A compound according to claim 1 , wherein the compound is selected from the group consisting of:

2-[Ethyl-(4-fluoro-benzenesulfonyl)-amino]-N-[1-(4-trifluoromethyl-phenyl)-piperidin-3-ylmethyl]-acetamide;

2-[(4-Fluoro-benzenesulfonyl)-isopropyl-amino]-N-[1-(4-trifluoromethyl-phenyl)-piperidin-3-ylmethyl]-acetamide;

2-[Ethyl-(4-fluoro-benzenesulfonyl)-amino]-N-[1-(4-trifluoromethyl-phenyl)-pyrrolidin-3-ylmethyl]-acetamide;

2-[(4-Fluoro-benzenesulfonyl)-isopropyl-amino]-N-[1-(4-trifluoromethyl-phenyl)-pyrrolidin-3-ylmethyl]-acetamide;

2-[(4-Fluoro-benzenesulfonyl)-isopropyl-amino]-N-[(S)-1-(4-trifluoromethyl-phenyl)-piperidin-3-ylmethyl]-acetamide;

2-[(4-Fluoro-benzenesulfonyl)-isopropyl-amino]-N-[(R)-1-(4-trifluoromethyl-phenyl)-piperidin-3-ylmethyl]-acetamide;

2-[(4-Fluoro-benzenesulfonyl)-methyl-amino]-N-[4-(4-trifluoromethyl-phenyl)-morpholin-2-ylmethyl]-acetamide;

2-[(4-Fluoro-benzenesulfonyl)-isopropyl-amino]-N-[4-(4-trifluoromethyl-phenyl)-morpholin-2-ylmethyl]-acetamide;

2-[Ethyl-(4-fluoro-benzenesulfonyl)-amino]-N-[4-(4-trifluoromethyl-phenyl)-morpholin-2-ylmethyl]-acetamide;

2-[(4-Fluoro-benzenesulfonyl)-isopropyl-amino]-N-[(R)-4-(4-trifluoromethyl-phenyl)-morpholin-2-ylmethyl]-acetamide;

2-[(4-Fluoro-benzenesulfonyl)-isopropyl-amino]-N-[(S)-4-(4-trifluoromethyl-phenyl)-morpholin-2-ylmethyl]-acetamide; and

2-[(4-Fluoro-benzenesulfonyl)-isopropyl-amino]-N-[4-(5-trifluoromethyl-pyridin-2-yl)-morpholin-2-ylmethyl]-acetamide.

14. A process for the manufacture of a compound of formula (I) comprising the reaction of a compound of formula (A)

in the presence of a compound of formula (B)

a coupling agent and a base, wherein R1 to R3 are as defined in claim 1 .

15. A compound according to claim 1 when manufactured by the process of claim 14 .

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

17. A method for the treatment of a respiratory disorder, the method comprising administering a therapeutically effective amount of a compound according to claim 1 to a subject in need thereof.

18. The method of claim 17 , wherein the respiratory disorder is selected from the group consisting of chronic obstructive pulmonary disorder (COPD), asthma, allergic rhinitis and bronchospasm.

Continuity (3)
Continuation PCTEP2013073521 · Nov 11, 2013
Provisional Application 61726154 · Nov 14, 2012
Related Publication 20150246906A1 · Sep 3, 2015